Stock Price Forecast

March 15, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading AnaptysBio Inc chart...

About the Company

founded in 2005, anaptysbio, inc. is a privately-held company focused on the generation of antibody therapeutics, and the leader in the use of somatic hypermutation (shm) for antibody discovery and optimization. anaptysbio is building a pipeline of novel therapeutic antibody product candidates, including differentiated programs in cancer immunotherapy, inflammation, muscle wasting disorders, fibrosis and antibody-drug conjugate applications. anaptysbio’s proprietary shm-xel platform, which couples fully human antibody libraries with in vitro somatic hypermutation (shm) in mammalian cells to generate high affinity lead candidates, replicates key features of the human immune system and overcomes limitations of prior antibody technologies. by harnessing the natural mechanism of antibody maturation under controlled conditions, shm-xel allows for the selection of optimal antibody properties such as high affinity, function, cross-reactivity, epitope diversity and manufacturability. the c

CEO

Hamza Suria

Exchange

NASDAQ

Website

https://www.anaptysbio.com/

$156M

Total Revenue

102

Employees

$624M

Market Capitalization

-4.18

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $ANAB News

Industry Analysts Just Made A Stunning Upgrade To Their AnaptysBio, Inc. (NASDAQ:ANAB) Revenue Forecasts

17h ago, source:

AnaptysBio, Inc. ( NASDAQ:ANAB) shareholders will have a reason to smile today, with the analysts making substantial upgrades ...

Skin Disease-Focused AnaptysBio Earns Analyst Upgrade On Positive Outlook For Clinical Triggers

6d ago, source:

AnaptysBio exceeds Q4 2023 earnings expectations, with sales of $9.01 million. Expectations high post-Wedbush upgrade, ...

What Makes AnaptysBio, Inc. (ANAB) a New Buy Stock

4d ago, source: Zacks.com on MSN

AnaptysBio, Inc. (ANAB) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting ...

Wall Street Analysts Believe AnaptysBio, Inc. (ANAB) Could Rally 69.62%: Here's is How to Trade

4d ago, source: Zacks.com on MSN

AnaptysBio, Inc. (ANAB) closed the last trading session at $24.69, gaining 10.8% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall ...

Strong Buy Rating for AnaptysBio Based on Promising Pipeline and Financial Health

7d ago, source:

TD Cowen analyst Joseph Thome has maintained their bullish stance on ANAB stock, giving a Buy rating on February 26. Joseph Thome has given ...

Wedbush raises AnaptysBio to outperform, cites upcoming data

6d ago, source:

Wedbush upped AnaptysBio (ANAB) to outperform, stating it sees upcoming clinical and derivative catalysts driving the shares ...

AnaptysBio, Inc. (ANAB) Reports Q4 Loss, Tops Revenue Estimates

7d ago, source: Zacks.com on MSN

AnaptysBio, Inc. (ANAB) delivered earnings and revenue surprises of 8.62% and 174.29%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

AnaptysBio Inc.

5d ago, source: Barron's

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International stock ...

AnaptysBio files patent for anti-TIM-3 antibodies for treating diseases

7d ago, source: Pharmaceutical Technology

Discover how AnaptysBio's patent for anti-TIM-3 antibodies targets cancer, infectious, and autoimmune diseases with specific sequences for optimal efficacy.

AnaptysBio, Inc.: Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

7d ago, source: Finanznachrichten

AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported operating results for the fourth quarter and year ended ...

Analysts Estimate Lexicon Pharmaceuticals (LXRX) to Report a Decline in Earnings: What to Look Out for

18d ago, source: Zacks.com on MSN

Lexicon (LXRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...